2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Biological Processes, Pathogenesis, Hematopoiesis, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Pediatric
PAPER

3147 Paracrine protection of myelopoiesis by bone marrow CD37⁺ macrophage-like myeloid suppressor cells during inflammatory stress

Alexandra Pommier, PhD, Abhishek Singh, PhD2, Laura M Dionisio, PhD3, Parash Prasad, PhD4, Shaivi M Latevi, PhD5, Annemiek van Spriel, PhD6, Marcela V. Maus, MD, PhD7, Jose A Cancelas, MD, PhD8
1 Dana Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana Farber Cancer Institute, Boston, Massachusetts, United States
6 Radboud UMC, Nijmegen, Netherlands
7 Mass General Brigham, Boston, Massachusetts, United States
8 Dana Farber Cancer Institute, Boston, Massachusetts, United States

Chimeric antigen receptor (CAR)-T cell therapy has produced remarkable clinical responses in relapsed/refractory B-cell malignancies. CAR-37, a novel CD37-directed CAR-T product, has demonstrated promising clinical activity but is associated with prolonged severe myeloid cytopenias that are not reproduced in xenograft models, suggesting that depletion of endogenous bone marrow (BM) niche cells, rather than direct hematopoietic stem and progenitor cell (HSPC) toxicity, underlies these adverse events. We hypothesized that a previously unrecognized CD37⁺ BM-resident macrophage population suppresses inflammatory stress and supports hematopoiesis. Flow cytometric analysis of wild-type (WT) murine BM demonstrated CD37 expression on approximately 60% of B cells, 9% of T cells, 5% of NK cells, and 3% of myeloid cells, whereas normal HSPCs lacked detectable surface CD37 expression, indicating that CAR-37-associated hematopoietic toxicity is unlikely to result from direct HSPC targeting. Immunofluorescence imaging demonstrated that CD37⁺ macrophage-like cells can be found adjacent to endosteal osteoblast-rich regions, consistent with a specialized role in maintaining the hematopoietic microenvironment. Multiplex cytokine profiling of co-cultures of purified CD37+ BM cells revealed enrichment of CXCL12 expression after LPS stimulation. Transwell co-culture experiments showed that CD37⁺ BM cells completely prevented the approximately 40% reduction in myeloid colony-forming units (CFUs) induced by ultrapure E. coli lipopolysaccharide (5 ng/mL, 16 h), demonstrating that protection is mediated by soluble factors independent of direct cell-cell contact. Selective depletion experiments identified CD37⁺ myeloid cells as the principal contributors, whereas depletion of B or NK cells had no measurable effect. Moreover, purified CD11b⁺F4/80⁺CD37⁺ macrophages alone fully restored hematopoietic colony formation after inflammatory stress, establishing these cells as the dominant functional component of the protective niche. In contrast, macrophages from CD37-/- mice failed to rescue CFU activity despite comparable viability, demonstrating that CD37 is functionally required for macrophage-mediated hematopoietic support rather than serving solely as a lineage marker. CD37-/- macrophages had demonstrable decreased expression of CXCL12, IL-4 and IL-10 and increased expression of TGF-ß, consistent with a potential anti-inflammatory role of CD37+ BM macrophages. Single-cell RNA sequencing of CD11b⁺ BM cells from WT and CD37-deficient mice revealed expansion of inflammatory tissue-resident M1-like macrophages and myeloid progenitors in CD37-/- BM. Differential expression analysis demonstrated activation of interferon and TNFα/NF-κB inflammatory pathways, while cell-cell communication analysis predicted disrupted macrophage-HSPC signaling networks, providing a mechanistic explanation for impaired progenitor maintenance. To establish clinical relevance, we identified an analogous CD37⁺ macrophage population comprising approximately 40% of human CD11b⁺CD68⁺ BM macrophages. Human CD34⁺ progenitor-derived CD37⁺ macrophages were efficiently recognized and eliminated by CAR-37 T cells and successfully homed to the BM following adoptive transfer into NOD/SCID/IL2Rγ-/- (NSG) mice, establishing a translational model to evaluate CAR-T efficacy and hematopoietic toxicity. Collectively, these findings identify a previously unrecognized CD37⁺ BM-resident macrophage population that preserves HSPC function by suppressing inflammatory stress through paracrine signaling. We propose that on-target depletion of these supportive macrophages, rather than direct HSPC killing, provides a mechanistic explanation to the development of prolonged myeloid cytopenias following CD37-directed CAR-T therapy and may also contribute to immune-mediated cytopenias associated with other cellular immunotherapies. These studies establish a new paradigm for CAR-T-associated hematologic toxicity and provide a rationale for macrophage- or niche-directed strategies that preserve hematopoiesis without compromising antitumor efficacy.

Alexandra Pommier, PhD: No relevant conflicts of interest to declare.